StockData
Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc. (ANIK) stock

ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/30
$12.85−0.07 (-0.54%)

Close on Nov 17, 2026Market cap $171.97MP/E –Yield –

Earnings

Anika Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$30.60M
+10.1% on a year earlier
Adjusted EPS, Q3 FY2026
-$0.02
$0.04 a year earlier
Latest guidance
Raised
Nov 6, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Anika Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 6, 2026before the open$30.60M+10.1%-$0.02–Release
Q2 FY2026ended Jun 30, 2026Jul 29, 2026before the open$32.60M+15.6%$0.24–Release
Q1 FY2026ended Mar 31, 2026Apr 29, 2026before the open$29.60M+13.0%-$0.37$0.27Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$30.60M0.0%$0.13$0.31Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025before the open$27.80M-28.4%–$0.04Release
Q2 FY2025ended Jun 30, 2025Jul 30, 2025before the open$28.20M-32.7%-$0.33-$0.13Release
Q1 FY2025ended Mar 31, 2025May 9, 2025before the open$26.20M-35.3%-$0.28-$0.06Release
Q4 FY2024ended Dec 31, 2024Mar 12, 2025during market hours$30.60M-28.8%-$0.17-$0.03Release
Q3 FY2024ended Sep 30, 2024Oct 31, 2024before the open$38.80M-6.5%-$2.03-$0.25Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours$41.90M-5.4%-$0.01$0.17Release
Q1 FY2024ended Mar 31, 2024May 8, 2024during market hours$40.50M+6.9%-$0.31$0.09Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Anika Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Commercial Channel revenue growthFY2026+12% – +18%+1% – +9%RaisedJul 29, 2026
Total Company RevenueFY2026$114.00M – $122.50M–NewApr 29, 2026
Total Company RevenueGAAPFY2026$114.00M – $122.50M–NewFeb 26, 2026
Total Company revenue growthFY2026+6% – +10%+10% – +20%LoweredNov 6, 2026
Adjusted EBITDA marginnon-GAAPFY202615% – 17%5% – 10%RaisedNov 6, 2026
Adjusted EBITDA as a percent of revenuenon-GAAPFY20265% – 10%–NewApr 29, 2026
Adjusted EBITDA marginnon-GAAPFY202613% – 17%–RaisedJul 29, 2026
Commercial Channel growthFY2027+10% – +20%–NewJul 30, 2025
Commercial Channel revenue growthFY2027+5% – +15%–NewJul 29, 2026
initial sales for HyalofastFY2027$3.00M–NewJul 30, 2025

Guidance vs results

The last range Anika Therapeutics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$47.00M – $49.50M$112.80MΣ4QAbove range
FY2025Revenue growth+12% – +18%-25.69%Σ4QBelow range

Guidance history

Every forecast Anika Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 6, 2026Adjusted EBITDA marginFY202615% – 17%Raised
Nov 6, 2026Total Company revenue growthFY2026+6% – +10%Lowered
Jul 29, 2026Adjusted EBITDA marginFY202613% – 17%Raised
Jul 29, 2026Commercial Channel revenue growthFY2026+12% – +18%Raised
Jul 29, 2026Total Company Revenue GuidanceFY2026+5% – +10%Lowered
Jul 29, 2026Commercial Channel revenue growthFY2027+5% – +15%New
Jul 29, 2026OEM Channel revenue growthFY20260% – +5%Lowered
Apr 29, 2026Adjusted EBITDA as a percent of revenueFY20265% – 10%New
Apr 29, 2026Total Company Revenue growthFY2026+1% – +9%New
Apr 29, 2026Commercial Channel growthFY2026+10% – +20%Raised
Apr 29, 2026Total Company RevenueFY2026$114.00M – $122.50MNew
Apr 29, 2026Commercial ChannelFY2026$53.00M – $58.00MLowered
Apr 29, 2026OEM ChannelFY2026$61.00M – $64.50MRaised
Feb 26, 2026Adjusted EBITDA as a percent of revenueFY20265% – 10%New
Feb 26, 2026Total Company RevenueFY2026$114.00M – $122.50MNew
Nov 5, 2025Adjusted EBITDA as a percent of revenueFY2025-3% – 3%New
Nov 5, 2025Commercial Channel growthFY2025+12% – +18%New
Nov 5, 2025OEM Channel growthFY2025-20% – -16%Lowered
Nov 5, 2025Commercial ChannelFY2025$47.00M – $49.50MNew
Nov 5, 2025OEM ChannelFY2025$62.00M – $65.00MRaised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Anika Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Update
  10. Results
  11. Results
  12. Update
  13. Results
  14. Update
  15. Results

See a number that looks wrong?